For ovarian cancer patients: Histologically confirmed surgical diagnosis of high-grade serous (or undifferentiated) ovarian cancer

For CIN3 and cervical cancer patients: Histologically confirmed diagnosis of CIN3 or cervical cancer

For AML and CML patients: HLA-A2 positivity and diagnosis of AML or CML confirmed by bone marrow biopsy or peripheral blood

No evidence of active progressive disease. For ovarian cancer patients, a woman with a rising CA125 and negative imaging is acceptable

Age ≥ 18 yrs and \< 70 yrs

ECOG 0-2

Adequate hematologic assessment (results from the previous standard of care visit):

Absolute neutrophil count (ANC) greater than or equal to 1.0 x 109/L

Platelets greater than or equal to 100 x 109/L.

Written informed consent

Persistent fever (\>24 hours) documented by repeated measurement or active uncontrolled infection in the last 4 weeks.

Active autoimmune disease, including, but not limited to, SLE, MS, ankylosing spondylitis.

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity